News

AmoyDx® Pan Lung Cancer PCR PanelApproved in Japan as a Companion Diagnostic indication of Amivantamab plus Lazertinib combination Therapy

TOKYO and XIAMEN, July 23, 2025 — Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx® PLC Panel”) as a companion diagnostic (CDx) for indication of Amivantamab plus Lazertinib combination Therapy in Japan.

Jul 23

AmoyDx® Pan Lung Cancer PCR Panel application for approval in Japan as a Primary Companion Diagnostic for Taletrectinib

TOKYO and XIAMEN, March 27, 2025 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co., Ltd....

Mar 28

AmoyDx® Pan Lung Cancer PCR Panel application for approval in Japan as a Companion Diagnostic for LORBRENA ® Lorlatinib

TOKYO and XIAMEN, February 6th, 2025 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co.,...

Feb 6

NCC to initiate new research to develop nationwide Clinical Trial Network, LC-SCRUM-CD (Clinical Development), supported by PREMIA and Paradigm, to further accelerate precision medicine for patients.

The National Cancer Center (“NCC”), Precision Medicine Asia Co., Ltd. (“PREMIA”) and Paradigm Health Inc (“Paradigm”), announced the...

Nov 5, 2024

AmoyDx® Pan Lung Cancer PCR PanelApproved in Japan as a Companion Diagnosticfor AUGTYRO® (repotrectinib)

TOKYO and XIAMEN, September 25th, 2024 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia...

Sep 25, 2024

AmoyDx® Pan Lung Cancer PCR PanelApproved in Japan as a Companion Diagnosticfor Haiyitan® tablets (gumarontinib hydrate)

TOKYO and XIAMEN, July 25th, 2024 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co.,...

Jul 29, 2024